Arecor Therapeutics' (LON:AREC) CEO Sarah Howell joins Proactive London to talks through their latest results and pipeline, including the expected completion of a US Phase I clinical trial for ultra-rapid acting insulin AT247.
Howell explains how their rapid insulin has shown significant promise in an early-stage clinical trial with results from the Phase I clinical trial for AT278, an ultra-concentrated ultra-rapid acting insulin, showing better results than the widely marketed NovoRapid.
In the six months ended 30 June, revenue came in at £500,000 from £800,000 the year before, with loss after tax of £3mln from £1mln in 2020.
Investment in R&D was £1.9mln, with cash and cash equivalents sitting at £22mln at period-end.